Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of MS-325 MRI Imaging Agent

WELLESLEY HILLS, Massachusetts, April 12, 2010 - Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of
Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the
MRI imaging intellectual properties will be auctioned on May 28, 2010. The
assets of Epix were transferred to him on July 20, 2009 and he is liquidating
them for the benefit of Epix creditors. He recently reached an agreement with
Bayer Schering Pharma that permits the sale of the MRI imaging programs.

The family of gadolinium-based imaging programs consists of MS-325
(gadofosveset trisodium), which is a commercial MRA imaging agent currently
marketed as Ablavar(R) in the US by Lantheus Medical Imaging and formerly
marketed as Vasovist(R) in Europe and other countries by Bayer Schering
Pharma. MS-325 has been approved in 38 countries. The MS-325 commercial
rights for sale include European Union, Switzerland and other regions outside
the US, Canada, Puerto Rico and Australia.

MS-325 is a first-in-class gadolinium-based imaging agent that binds
reversibly to serum albumin. Because albumin is at a high concentration in
the blood stream, MS-325 remains in circulation for an extended period of
time, providing extended intravascular enhancement compared to existing
extracellular MR contrast agents.

Persons interested in bidding must sign a Confidentiality Disclosure
Agreement ("CDA") obtained from Finn's Office -
IPSALESERVICES@FINNWARNKEGAYTON.COM or +1-781-237-8840. They will then
receive a bid package and access to an electronic data room.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the owner of the firm, Finn, Warnke &
Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He
works primarily in the area of management consulting for distressed
enterprises, bankruptcy accounting and related matters, such as assignee for
the benefit of creditors and liquidating agent for a corporation. He has been
involved in a number of loan workouts and bankruptcy cases for thirty-five
(35) years. His most recent Assignments for the Benefit of Creditors in the
biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect
Therapeutics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at
+1-781-237-8840 or IPSALESERVICES@FINNWARNKEGAYTON.COM

Joseph F. Finn, Jr., C.P.A., +1-781-237-8840, IPSALESERVICES at FINNWARNKEGAYTON.COM